Procter & Gamble (P&G) has agreed to acquire Thorne, a leader in science-backed health and wellness solutions, to strengthen its position in the premium wellness market. Thorne, trusted by healthcare practitioners and consumers since 1984, offers high-quality nutritional supplements and innovative health technology. The acquisition aims to help Thorne expand its impact while maintaining its commitment to science, quality, and personalized health. The deal is expected to close later this year, pending regulatory approvals.
Procter & Gamble, Johnson & Johnson, and Coca-Cola are set to reach target prices of $180, $300, and $100 respectively by 2027, driven by their strong dividend histories and growth catalysts. PG aims for $180 supported by productivity gains and stead...
L Catterton, a leading consumer investment firm, has agreed to sell Thorne, a science-backed wellness brand, to Procter & Gamble for $3.8 billion in cash. Since investing in Thorne in 2023, L Catterton accelerated its growth by enhancing leadership, ...
